1427P - Analysis of treatment patterns of patients with advanced gastrointestinal stromal tumors (GIST) in EU5

Date 29 September 2014
Event ESMO 2014
Session Poster Display session
Topics Bioethics, Legal, and Economic Issues
GIST
Presenter Katja Jehle
Citation Annals of Oncology (2014) 25 (suppl_4): iv494-iv510. 10.1093/annonc/mdu354
Authors K. Jehle1, M. Rabiller2, S. Grippon1, G. Haas1, C. Ngai3, A.F. Mohamed3, J. Chang3
  • 1Global Oncology, IMS Health, 60598 - Frankfurt am Main/DE
  • 2Ce Consulting, IMS Health, 60598 - Frankfurt am Main/DE
  • 3Gheor, Specialty Medicine, Bayer Healthcare Pharmaceuticals Inc., Whippany/US

Abstract

Aim

Real world data on treatment (tx) patterns in advanced GIST is sparse; our study provides an overview of the distribution of advanced GIST patients (pts) in lines of therapy and tx regimen.

Methods

161 tx records in EU5 (Germany, France, Spain, Italy, UK) were analyzed with a cross-sectional GIST enhanced tumor study (ETS) set up by IMS Health. The ETS entails information on pts demographics, full tx history and information on supportive therapies. Each medical record was analyzed with regards to current and historic therapies and regimen.

Results

Distribution of pts (n=161) across lines of therapy and tx regimen is summarized in the table. While 77.5% of pts are in 1st therapy, 22.5% are in 2nd therapy. Patients that are in 3rd line therapy and beyond were not taken in consideration for this analysis. 86% of 1st therapy pts are receiving imatinib (IM)400 while 10% receive IM800, 2% receive sunitinib (SUN), 1% are on supportive* therapy and 1% are on other TKI's. 93% of pts in 2nd therapy had IM400 and 7% had SUN as their 1st therapy. Among the 2nd therapy pts who had IM400 as their 1st therapy, 72.5% receive SUN, 15% IM800; 10% IM400 and 2.5% regorafenib (REG). Among the 2nd therapy pts who had SUN as their 1st therapy, 33% receive SUN and 67% IM400. Distribution of patients#

Tx Regimen 1st (77.5%) 2nd (22. 5%)
IM400 in 1st therapy (93%) SUN in 1st therapy (7%)
IM400 86% 10% 67%
IM800 10% 15% -
SUN 2% 72.5% 33%
Supportive* 1% - -
Other TKI's 1% - -
REG - 2.5% -

#Patients that are in 3rd line therapy and beyond were not taken in consideration for this analysis *Supportive: All molecules excl cytostatic drugs Source: IMS ETS Q4 2013, EU5 countries

Conclusions

This analysis suggests that advanced GIST is treated with TKIs per guideline recommendations in EU5. However, non-evidence based practice was observed. Patients were continued with IM400 as 2nd therapy even though it is not recommended. The use of SUN in 1st therapy is likely to be due to IM intolerance; however, the rationale for treating these patients with IM400 as 2nd therapy is unclear.

Disclosure

K. Jehle, M. Rabiller, S. Grippon and G. Haas: The study detailed in the abstract was funded by Bayer Healthcare Pharmaceuticals, Inc.; C. Ngai, A.F. Mohamed and J. Chang: is an employee of Bayer Healthcare Pharmaceuticals, Inc. The study detailed in the abstract was funded by Bayer Healthcare Pharmaceuticals, Inc.